Alpha-1-Antitrypsin-Mangel (AATM) – Ein Expertenstatement

T. Greulich; S. Fähndrich; C. Clarenbach; W. Gleiber; H. Hautmann; R. Heine; M. Idzko; K. Schmidt-Scherzer; D. Skowasch; R. Wiewrodt; R. Bals; A. R. Koczulla

doi:10.1055/a-1143-8186

Pneumologie, Table of Contents

Pneumologie 2020; 74(07): 436-442
DOI: 10.1055/a-1143-8186

Positionspapier der DGP

Alpha-1-Antitrypsin-Mangel (AATM) – Ein Expertenstatement

Alpha-1 Antitrypsin Deficiency (AATD) – D-A-CH-Expert Statement

T. Greulich

¹Klinik für Innere Medizin, Schwerpunkt Pneumologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philips-Universität, Marburg

²PneumoPraxis-Marburg, Marburg

,

S. Fähndrich

³Medizinische Klinik und Poliklinik Innere Medizin V Abteilung Pneumologie, Universitätsklinikum Freiburg, Freiburg

,

C. Clarenbach

⁴Universitätsspital Zürich, Klinik für Pneumologie, Zürich, Schweiz

,

W. Gleiber

⁵Medizinische Klinik I: Pneumologie und Allergologie, Universitätsklinikum Frankfurt am Main, Goethe-Universität, Frankfurt am Main

,

H. Hautmann

⁶Klinik für Innere Medizin und Pneumologie, Klinikverbund Allgäu, Ottobeuren

,

R. Heine

⁷Krankenhaus St. Elisabeth und St. Barbara, Halle

,

M. Idzko

⁸Medizinische Universität Wien, Klinik für Innere Medizin II, Wien, Österreich

,

K. Schmidt-Scherzer

⁹Zweite Medizinische Abteilung mit Pneumologie mit Ambulanz, Wilhelminenspital, Wien, Österreich

,

D. Skowasch

¹⁰Medizinische Klinik + Poliklinik II Schwerpunkt Pneumologie, Universitätsklinikum Bonn, Rheinische Friedrich-Wilhelm-Universität, Bonn

,

R. Wiewrodt

¹¹Medizinische Klinik A Schwerpunkt Pneumologie, Universitätsklinikum Münster, Münster

,

R. Bals

¹²Klinik für Innere Medizin V, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg

,

A. R. Koczulla

¹Klinik für Innere Medizin, Schwerpunkt Pneumologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philips-Universität, Marburg

¹³Fachzentrum für Pneumologie, Schön Klinik Berchtesgadener Land, Schönau am Königssee

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Jeppsson JO. Amino acid substitution Glu leads to Lys alpha1-antitrypsin PiZ. FEBS Lett 1976; 65: 195-197
2 Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency--a model for conformational diseases. N Engl J Med 2002; 346: 45-53
3 Beckman G, Stjernberg NL, Eklund A. Is the PiF allele of alpha 1-antitrypsin associated with pulmonary disease?. Clin Genet 1984; 25: 491-495
4 Hutchison DC. Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir Med 1998; 92: 367-377
5 Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294: 1316-1321
6 Dahl M. et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med 2002; 136: 270-279
7 Blanco I. et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 2006; 27: 77-84
8 Stoller JK. et al. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med 1994; 61: 461-467
9 Greulich T. et al. An electronic nose can distinguish between different asthma phenotypes. Eur Respir J 2013; 42: P3551
10 ATS/ERS, American Thoracic Society/European Respiratory Society. statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818-900
11 Sandhaus RA. et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis 2016; 3: 668-682
12 Bals R. et al. Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med 2007; 101: 1708-1714
13 Ferrarotti I. et al. Laboratory diagnosis of alpha1-antitrypsin deficiency. Transl Res 2007; 150: 267-274
14 Snyder MR. et al. Diagnosis of alpha-1-antitrypsin deficiency: An algorithm of quantification, genotyping, and phenotyping. Clin Chem 2006; 52: 2236-2242
15 Steiner SJ. et al. Serum levels of alpha1-antitrypsin predict phenotypic expression of the alpha1-antitrypsin gene. Dig Dis Sci 2003; 48: 1793-1796
16 Ferrarotti I. et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax 2012; 67: 669-674
17 Greulich T. et al. European screening for alpha -antitrypsin deficiency in subjects with lung disease. Clin Respir J 2015;
18 Greulich T. et al. Real world evaluation of a novel lateral flow assay (AlphaKit(R) QuickScreen) for the detection of alpha-1-antitrypsin deficiency. Respir Res 2018; 19: 151
19 Miravitlles M. et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur Respir J 2017; 50: 1700610
20 Piitulainen E, Mostafavi B, Tanash HA. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years. Int J Chron Obstruct Pulmon Dis 2017; 12: 495-500
21 Campos MA. et al. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest 2009; 135: 600-608
22 Seersholm N, Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency. Thorax 1998; 53: 265-268
23 Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77: 14-27
24 Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J 1999; 13: 247-251
25 Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985; 1: 152-154
26 Stoller JK. et al. Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry. Chest 2005; 127: 1196-1204
27 Dawkins PA. et al. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003; 58: 1020-1026
28 Horvath I. et al. Diagnosis and management of alpha1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res 2019; 5: 00171-2018
29 Miravitlles M. et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur Respir J 2017; 50: pii: 1700610
30 Vogelmeier C. et al. Guideline for the Diagnosis and Treatment of COPD Patients – Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology. Pneumologie 2018; 72: 253-308
31 Singh D. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 2019; 53: pii: 1900164
32 Dirksen A. et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33: 1345-1353
33 Chapman KR. et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6: 177-184
34 Stockley RA. et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 136
35 Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010; 09: CD007851
36 Dirksen A. et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468-1472
37 Chapman KR. et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 360-368
38 McElvaney NG. et al. Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med 2017; 5: 51-60
39 Stoller JK. et al. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest 2002; 122: 66-74
40 Stocks JM. et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD 2006; 3: 17-23
41 Stocks JM. et al. Pharmacokinetic comparability of Prolastin(R)-C to Prolastin(R) in alpha(1)-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol 2010; 10: 13
42 Campos MA. et al. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). COPD 2013; 10: 687-695
43 Sandhaus RA. et al. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous). COPD 2014; 11: 17-25
44 The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998; 158: 49-59
45 Seersholm N. et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10: 2260-2263
46 Stoller JK. et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003; 123: 1425-1434
47 Wencker M. et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119: 737-744
48 Tonelli AR. et al. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis 2009; 4: 443-452
49 Barros-Tizon JC. et al. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis 2012; 6: 67-78
50 Wewers MD. et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062
51 Schmidt EW. et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease. Am J Med 1988; 84: 63-69
52 Barker AF. et al. Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration. Chest 1994; 105: 1406-1410
53 Barker AF. et al. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997; 112: 607-613
54 Miravitlles M. et al. Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency. Arch Bronconeumol 1994; 30: 479-484
55 Schwaiblmair M, Vogelmeier C, Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency -- three-year follow-up. Respiration 1997; 64: 10-15
56 Wencker M. et al. Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin. Pneumologie 1998; 52: 545-552
57 Wencker M. et al. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11: 428-433
58 Campos MA. et al. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir Med 2009; 103: 1532-1539
59 Subramanian DR. et al. Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. Am J Respir Crit Care Med 2012; 186: 1125-1132
60 Ma S. et al. The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. Chronic Obstr Pulm Dis 2016; 4: 34-44
61 Fahndrich S. et al. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency. Respir Med 2017; 129: 8-15
62 Dowson LJ. et al. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J 2001; 17: 1097-1104
63 Dawkins P. et al. Mortality in alpha-1-antitrypsin deficiency in the United Kingdom. Respir Med 2009; 103: 1540-1547
64 Green CE. et al. Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respir Med 2016; 112: 81-87
65 Campos MA. et al. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy: A Pilot Study. Am J Respir Crit Care Med 2019; 200: 318-326
66 Kohnlein T. et al. Expert statement for augmentation therapy in patients with alpha-1 antitrypsin deficiency. Pneumologie 2014; 68: 492-495